Search

Displaying results 2701 - 2710 of 5506 in total
  1. Drug

    Caroxazone

    go.drugbank.com/drugs/DB09254
    ApprovedWithdrawn

    It is a reversible monoamine oxidase inhibitor (MAOI) of both A and B monoamine oxidase subtypes. However, it presents a five-fold preference for the MAO-B subtype.

  2. Drug

    Phosphocreatine

    go.drugbank.com/drugs/DB13191
    InvestigationalNutraceutical

    It is primarily found endogenously in the skeletal muscles of vertebrates where it serves a critical role as a rapidly acting energy buffer for muscle cell actions like contractions via its ability to

  3. Drug

    Imiquimod

    go.drugbank.com/drugs/DB00724
    ApprovedInvestigational

    Imiquimod does not fight the viruses that cause warts directly, however, it does help to relieve and control wart production.

  4. Drug

    Parecoxib

    go.drugbank.com/drugs/DB08439
    ApprovedInvestigational

    As it is injectable, it can be used perioperatively when patients are unable to take oral medications. … It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx).

    Products: DYNASTAT INJECTION 40MG, Dynastat Injection 40mg
  5. Drug

    Penicillium expansum

    go.drugbank.com/drugs/DB10810
    Approved

    Penicillium expansum is a fungus which can provoke allergic reactions. Penicillium expansum extract is used in allergenic testing.

    Mixtures: Treatment Set TS333938
  6. Drug

    Spinosad

    go.drugbank.com/drugs/DB08823
    ApprovedVet approved

    Spinosad is a pediculicide mixture of spinosyn A and spinosyn D (in an approximately 5:1 ratio, respectively) used in the topical treatment of head lice in children (four years old and older) and in adults. Spinosad is an insecticide bas...

  7. Drug

    CHGN111

    go.drugbank.com/drugs/DB06376
    Experimental

    It was under investigation until approximately 2007. … Numerous parameters of mitochondrial function are altered when the activity of CLK-1 is reduced, which results in a decrease of ROS at critical cellular sites, as well as in a decrease of systemic oxidative

  8. Drug

    Gadopiclenol

    go.drugbank.com/drugs/DB17084
    ApprovedInvestigational

    [A254002] Gadopiclenol has high kinetic stability and a high r1 relaxivity, allowing it to be used at lower doses than classic extracellular GBCAs. … It is indicated for use with magnetic resonance imaging (MRI) to detect and visualize lesions with abnormal vascularity in the central nervous system and the body.

  9. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [L53303,L53283] It is the first inhibitor of factor XIIa to receive market approval.[L53303] … [L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan.

  10. Drug

    Imlifidase

    go.drugbank.com/drugs/DB15258
    ApprovedInvestigational

    Chronic kidney disease (CKD) is a progressive and irreversible disease that represents a significant burden for both the individual and healthcare system at large. … [A225836,A225921] Highly sensitized individuals carry high levels of anti-HLA antibodies and are at significant risk for antibody-mediated rejection which occurs mainly through complement-dependent cytotoxicity